Pegaspargase

Specification

• Cat#: THP-0087
• Product Name: Pegaspargase
• Description: Pegylated L-asparagine amidohydrolase from E. coli. Pegylation substantially (by a factor of 4) extends the protein half life.
• Sequences: MEFFKKTALAALVMGFSGAALALPNITILATGGTIAGGGDSATKSNYTVGKVGVENLVNAVPQLKDIANVKGEQVVNIGSQDMNDNVWLTLAKKINTDCDKTDGFVITHGTDTMEETAYFLDLTVKCDKPVVMVGAMRPSTSMSADGPFNLYNAVVTAADKASANRGVLVVMNDTVLDGRDVTKTNTTDVATFKSVNYGPLGYIHNGKIDYQRTPARKHTSDTPFDVSKLNELPKVGIVYNYANASDLPAKALVDAGYDGIVSAGVGNGNLYKSVFDTLATAAKTGTAVVRSSRVPTGATTQDAEVDDAKYGFVASGTLNPQKARVLLQLALTQTKDPQQIQQIFNQY
• Species: E. coli
• Molecular Weight: 31731.9 Da
• Purity: >99% by SDS-Page and HPLC analysis
• Cas No: 130167-69-0
• Formula: C1377H2208N382O442S17
• Endotoxin Level: <0.001 EU per 1 μg by the LAL method
• Biological Activity: 750 U/1mL

Pharmaceutical Information

• Pharmaceutical Application: Pegaspargase
• Applications: For treatment of acute lymphoblastic leukemia.
• Examples of Clinical Use: Acute lymphoblastic leukemia
• Pharmacodynamics: In a significant number of patients with acute leukemia, the malignant cells are dependent on an exogenous source of asparagine for survival. Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase.
• Mechanism of action: Pegaspargase, more effective than asparaginase, converts asparagine to aspartic acid and ammonia. It facilitates production of oxaloacetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produce asparagine and so the loss of exogenous sources of asparagine leads to cell death.
• Affected organisms: Humans and other mammals